Relay Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +39.0%
EBITDA: +25.1%
EBIT: +19.2%
EPS: +29.6%
Free cash flow: +21.7%
Operating cash flow: +21.6%

Forward estimates

Revenue: -53.5%
EBITDA: +98.2%
EPS: +34.3%

Three-year CAGR

Revenue: +123.2%
EBITDA: +28.2%
EBIT: +18.7%
Net income: +18.1%
EPS: +31.8%
Free cash flow: +6.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.